Annis Gardner Whiting Capital Advisors LLC Has $923,000 Stock Position in Becton, Dickinson and Company $BDX

Annis Gardner Whiting Capital Advisors LLC boosted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 386.1% in the 3rd quarter, HoldingsChannel reports. The firm owned 4,934 shares of the medical instruments supplier’s stock after buying an additional 3,919 shares during the period. Annis Gardner Whiting Capital Advisors LLC’s holdings in Becton, Dickinson and Company were worth $923,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in BDX. Vanguard Group Inc. raised its stake in shares of Becton, Dickinson and Company by 15.4% in the second quarter. Vanguard Group Inc. now owns 32,308,749 shares of the medical instruments supplier’s stock valued at $5,565,182,000 after acquiring an additional 4,305,947 shares during the last quarter. Norges Bank acquired a new stake in Becton, Dickinson and Company during the 2nd quarter valued at $653,377,000. First Eagle Investment Management LLC raised its position in Becton, Dickinson and Company by 59.2% in the 2nd quarter. First Eagle Investment Management LLC now owns 8,786,190 shares of the medical instruments supplier’s stock valued at $1,513,421,000 after purchasing an additional 3,268,478 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Becton, Dickinson and Company by 24.4% in the second quarter. Massachusetts Financial Services Co. MA now owns 8,514,446 shares of the medical instruments supplier’s stock worth $1,466,613,000 after purchasing an additional 1,670,590 shares in the last quarter. Finally, Laurel Wealth Advisors LLC grew its holdings in shares of Becton, Dickinson and Company by 16,974.4% during the second quarter. Laurel Wealth Advisors LLC now owns 1,579,386 shares of the medical instruments supplier’s stock worth $272,049,000 after purchasing an additional 1,570,136 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Price Performance

Shares of BDX stock opened at $201.81 on Thursday. The firm’s 50 day moving average price is $198.08 and its two-hundred day moving average price is $190.98. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11. Becton, Dickinson and Company has a 52-week low of $162.29 and a 52-week high of $251.99. The stock has a market cap of $57.50 billion, a PE ratio of 34.62, a PEG ratio of 2.25 and a beta of 0.23.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 EPS for the quarter, beating the consensus estimate of $3.92 by $0.04. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The company had revenue of $5.89 billion during the quarter, compared to analysts’ expectations of $5.91 billion. During the same quarter in the previous year, the company posted $3.81 EPS. The business’s revenue for the quarter was up 8.3% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. As a group, analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company announced that its board has approved a share buyback plan on Tuesday, January 27th that permits the company to repurchase $10.00 million in shares. This repurchase authorization permits the medical instruments supplier to buy up to 0% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s leadership believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be issued a dividend of $1.05 per share. The ex-dividend date is Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a yield of 2.1%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 72.04%.

Insider Activity

In related news, Director Bertram L. Scott sold 217 shares of Becton, Dickinson and Company stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the transaction, the director owned 35,816 shares of the company’s stock, valued at $6,324,389.28. This trade represents a 0.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael David Garrison sold 1,610 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the sale, the executive vice president directly owned 12,095 shares of the company’s stock, valued at $2,509,228.70. The trade was a 11.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 2,680 shares of company stock valued at $539,848 over the last 90 days. Corporate insiders own 0.40% of the company’s stock.

Trending Headlines about Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Board set the record date (Feb 5) and distribution/closing date (Feb 9) for the spin-off of BD’s Biosciences & Diagnostic Solutions business — a structural move that could unlock value for shareholders. BD Announces Record Date for the Spin-Off
• Positive Sentiment: Waters Corporation shareholders approved the combination with BD’s Biosciences & Diagnostic Solutions unit, clearing a key step toward the planned transaction that underpins the spin-off strategy. Waters Shareholders Approve Combination
• Positive Sentiment: Board declared a $1.05 quarterly dividend (payable Mar 31; record/ex-div Mar 10), supporting income-focused investors and signaling cash-return discipline. BD Board Declares Dividend, Authorizes Repurchases
• Positive Sentiment: Company authorized an additional $10 million in share repurchases and has completed ~$250 million of repurchases year-to-date, which can support EPS and signal management confidence (note: $10M is small vs. market cap). Board Authorizes Additional Repurchases
• Positive Sentiment: Launched BD Research Cloud 7.0 with AI-powered features for flow cytometry — product innovation that can drive competitive positioning in diagnostics and recurring software/service revenue over time. BDX Introduces BD Research Cloud 7.0
• Neutral Sentiment: BD will release quarterly earnings and host a management webcast — an upcoming catalyst that could cause short-term volatility depending on results vs. guidance. BD to Release Quarterly Earnings
• Neutral Sentiment: Analyst and media pieces highlight BDX as a long-term value name versus peers; useful for investor sentiment but not an immediate price mover. Why Becton Dickinson is a Top Value Stock
• Negative Sentiment: Insider activity: EVP Michael Feld sold 75 shares (~$15.2k) on Jan 26 — a very small reduction in holdings (0.45% of his stake) that is unlikely to materially affect investor view but may be cited by short-term traders. SEC Form 4 – Michael Feld Sale

Wall Street Analyst Weigh In

A number of research firms recently issued reports on BDX. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Stifel Nicolaus raised their price objective on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Jefferies Financial Group upped their target price on shares of Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, December 10th. Bank of America increased their price target on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a research note on Monday, January 5th. Finally, Morgan Stanley boosted their price objective on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 2nd. Four equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Hold” and an average price target of $209.00.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.